Tag: Nonsmall cell lung cancer NSCLC

Browse exclusive Tags!

Johnson & Johnson Seeks EU Approval for Lazertinib + Rybrevant combo as First-Line Treatment for Advanced Non-Small Cell Lung Cancer

Johnson & Johnson seeks EU approval for a new combo treatment for advanced non-small cell lung cancer, offering hope for improved patient outcomes in EGFR mutations.

Promising Results: AbbVie’s Teliso-V Shows Impressive Response Rate in Lung Cancer Trial

Promising Phase 2 trial results show AbbVie's Teliso-V effectively targets c-Met overexpressing nonsquamous lung cancer, offering new hope for patients.

Bristol Myers Squibb’s Opdivo Regimen Shows Significant Improvement in Lung Cancer Survival Rates

Get the latest groundbreaking findings from Bristol Myers Squibb's Phase 3 trial on Opdivo regimen, showing significant improvement in lung cancer survival rates. Learn more here.

J INTS BIO Initiates Phase 1/2 Clinical Study of Novel EGFR TKI ‘JIN-A02’ for NSCLC Patients, South Korea

Learn about JIN-A02, a novel EGFR TKI for treating NSCLC patients. This Phase 1/2 study evaluates safety, pharmacokinetics, and anti-tumor activity.

Popular

Promising Results: AbbVie’s Teliso-V Shows Impressive Response Rate in Lung Cancer Trial

Promising Phase 2 trial results show AbbVie's Teliso-V effectively targets c-Met overexpressing nonsquamous lung cancer, offering new hope for patients.

J INTS BIO Initiates Phase 1/2 Clinical Study of Novel EGFR TKI ‘JIN-A02’ for NSCLC Patients, South Korea

Learn about JIN-A02, a novel EGFR TKI for treating NSCLC patients. This Phase 1/2 study evaluates safety, pharmacokinetics, and anti-tumor activity.

Johnson & Johnson Seeks EU Approval for Lazertinib + Rybrevant combo as First-Line Treatment for Advanced Non-Small Cell Lung Cancer

Johnson & Johnson seeks EU approval for a new combo treatment for advanced non-small cell lung cancer, offering hope for improved patient outcomes in EGFR mutations.

Subscribe

spot_imgspot_img